Novel chemical class of pUL97 protein kinase-specific inhibitors with strong anticytomegaloviral activity

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 11, 2004, Pages 4154-4162

  Herget, Thomas ^b,c   Freitag, Martina ^a   Morbitzer, Monika ^b   Kupfer, Regina ^a   Stamminger, Thomas ^a   Marschall, Manfred ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Axxima Pharmaceuticals AG   (Germany)

^c MERCK KGAA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AX 7376; AX 7396; AX 7543; CIDOFOVIR; EARLY LATE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GANCICLOVIR; GEFITINIB; GREEN FLUORESCENT PROTEIN; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PUL97 PROTEIN KINASE; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IC 50; KINETICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; VIRUS ADSORPTION; VIRUS ISOLATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BLOTTING, WESTERN; CELL LINE; CELLS, CULTURED; CYTOMEGALOVIRUS; CYTOSINE; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; GANCICLOVIR; HUMANS; PHOSPHONIC ACIDS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PLAQUE ASSAY; PLASMIDS; QUINAZOLINES; VIRUS REPLICATION;

EID: 7244224920     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.11.4154-4162.2004     Document Type: Article

References (31)

1. Biron, K. K., R. J. Harvey, S. C. Chamberlain, S. S. Good, A. A. Smith III, M. G. Davis, C. L. Talarico, W. H. Miller, R. Ferris, R. E. Dornsife, S. C. Stanat, J. C. Drach, L. B. Townsend, and G. W. Koszalka. 2002. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob. Agents Chemother. 46:2365-2372.
2. Blencke, S., A. Ullrich, and H. Daub. 2003. Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J. Biol. Chem. 278:15435-15440.
3. Borst, E. M., U. H. Koszinowski, and M. Messerle. 1999. Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J. Virol. 73:8320-8329.
4. Chulay, J., K. Biron, L. Wang, M. Underwood, S. Chamberlain, L. Frick, S. Good, M. Davis, R. Harvey, L. Townsend, J. Drach, and G. Koszalka. 1999. Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease. Adv. Exp. Med. Biol. 458:129-134.
5. Coen, D. M., and P. A. Schaffer. 2003. Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets. Nat. Rev. Drug Disc. 2:278-288.
6. Cohen, M. H., G. A. Williams, R. Sridhara, G. Chen, and R. Pazdur. 2003. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 8:303-306.
7. Erice, A. 1999. Resistance of human cytomegalovirus to antiviral drugs. Clin. Microbiol. Rev. 12:286-297.
8. Godl, K., J. Wissing, A. Kurtenbach, P. Habenberger, S. Blencke, H. Gutbrod, K. Salassisis, M. Stein-Gerlach, A. Missio, M. Cotten, and H. Daub. 2003. An efficient proteomics method to identify the cellular target of protein kinase inhibitors. Proc. Natl. Acad. Sci. USA 26:15434-15439.
9. Herget, T., S. A. Oehrlein, D. J. Pappin, E. Rozengurt, and P. J. Parker. 1995. The myristoylated alanine-rich C-kinase substrate (MARCKS) is sequentially phosphorylated by conventional, novel and atypical isotypes of protein kinase C. Eur. J. Biochem. 233:448-457.
10. Komazin, G., R. G. Ptak, B. T. Emmer, L. B. Townsend, and J. C. Drach. 2003. Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27. J. Virol. 77:11499-11506.
11. Koszalka, G. W., N. W. Johnson, S. S. Good, L. Boyd, S. C. Chamberlain, L. B. Townsend, L. C. Drach, and K. K. Biron, 2002. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimirob. Agents Chemother. 46:2373-2380.
12. Krosky, P. M., M.-C. Baek, and D. M. Coen. 2003. The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J. Virol. 77:905-914.
13. Krosky, P. M., M.-C. Baek, W. J. Jahng, I. Barrera, R. J. Harvey, K. K. Biron, D. M. Coen, and P. B. Sethna. 2003. The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase. J. Virol. 77:7720-7727.
14. Lalezari, J. P., J. A. Aberg, L. H. Wang, M. B. Wire, R. Miner, W. Snowden, C. L. Talarico, S. Shaw, M. A. Jacobsen, and W. L. Drew. 2002. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob. Agents Chemother. 46:2969-2976.
15. Littler, E., A. D. Stuart, and M. S. Chee. 1992. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 358:160-162.
16. Marschall, M., M. Freitag, P. Suchy, D. Romaker, R. Kupfer, M. Hanke, and T. Stamminger. 2003. The protein kinase pUL97 of human cytomegalovirus interacts with and phosphorylates the DNA polymerase processivity factor pUL44. Virology 311:60-71.
17. Marschall, M., M. Freitag, S. Weiler, G. Sorg, and T. Stamminger. 2000. Recombinant GFP-expressing human cytomegalovirus as a tool for screening of antiviral agents. Antimicrob. Agents Chemother. 44:1588-1597.
18. Marschall, M., M. Stein-Gerlach, M. Freitag, R. Kupfer, M. van den Bogaard, and T. Stamminger. 2001. Inhibitors of human cytomegalovirus replication drastically reduce the activity of the viral protein kinase pUL97. J. Gen. Virol. 82:1439-1450.
19. Marschall, M., M. Stein-Gerlach, M. Freitag, R. Kupfer, M. van den Bogaard, and T. Stamminger. 2002. Direct targeting of human cytomegalovirus protein kinase pUL97 by kinase inhibitors is a novel principle of antiviral therapy. J. Gen. Virol. 83:1013-1023.
20. McSharry, J. J., A. McDonough, B. Olson, C. Talarico, M. Davis, and K. K. Biron. 2001. Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94. Clin. Diagn. Lab. Immunol. 8:1279-1281.
21. Mett, H., K. Hölscher, H. Degen, C. Esdar, B. Felden de Neumann, B. Flicke, T. Freudenreich, G. Holzer, S. Schinzel, T. Stamminger, M. Stein-Gerlach, M. Marschall, and T. Herget. Identification of inhibitors for a virally encoded protein kinase by two different screening systems: in-vitro kinase assay and in-cell activity assay. J. Biomol. Screen, in press.
22. Müller, G. 2003. Medicinal chemistry of target family-directed masterkeys. Drug Discov. Today 8:681-691.
23. Pass, R. F. 2001. Cytomegaloviruses, p. 2675-2705. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, Pa.
24. Prichard, M. N., N. Gao, S. Jairath, G. Mulamba, P. Krosky, D. M. Coen, B. O. Parker, and G. S. Pari. 1999. A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J. Virol. 73:5663-5670.
25. Slater, M. J., S. Cockerill, R. Baxter, R. W. Bonser, K. Gohil, C. Gowrie, J. E. Robinson, E. Littler, N. Parry, R. Randall, and W. Snowden. 1999. Indolocarbazoles: potent, selective inhibitors of human cytomegalovirus replication. Bioorg. Med. Chem. 7:1067-1074.
26. Sullivan, V., C. L. Talarico, S. C. Stanat, M. Davis, D. M. Coen, and K. K. Biron. 1992. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 358:162-164.
27. Wang, L. H., R. W. Peck, Y. Yin, J. Allanson, R. Wiggs, and M. B. Wire. 2003. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 47:1334-1342.
28. Wang, X., S.-M. Huong, M. L. Chiu, N. Raab-Traub, and E.-S. Huang. 2003. Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. Nature 424:456-461.
29. Wolf, D. G., C. T. Courcelle, M. N. Prichard, and E. S. Mocarski. 2001. Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation. Proc. Natl. Acad. Sci. USA 98:1895-1900.
30. Zimmermann, A., D. Michel, I. Pavic, W. Hampl, A. Lüske, J. Neyts, E. De Clerq, and T. Mertens. 1997. Phosphorylation of aciclovir, genciclovir, penciclovir and S2242 by the cytomegalovirus UL97 protein: a quantitative analysis using recombinant vaccinia viruses. Antivir. Res. 36:35-42.
31. Zimmermann, A., H. Wilts, M. Lenhardt, M. Hahn, and T. Mertens. 2000. Indolocarbazoles exhibit strong antiviral activity against human cytomegalovirus and are potent inhibitors of the pUL97 protein kinase. Antivir. Res. 48:49-60.